Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001232524-26-000025
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Proceeds from maturity of investments | 520.0 | 310.0 |
| Proceeds from sale of priority review voucher | 200.0 | — |
| Payments related to sale of priority review voucher | (77.2) | — |
| Purchases of property, plant and equipment | (19.7) | (13.9) |
| Acquisition of investments | (500.0) | (440.1) |
| Acquisition of intangible assets | — | (25.0) |
| Net cash provided by (used in) investing activities | 123.1 | (169.0) |
| Financing activities |
Item 1.Financial Statements
FAQ
- What is Jazz Pharmaceuticals's capex?
- Jazz Pharmaceuticals (JAZZ) reported capex of $19.7M in Q1 2026.
- How has Jazz Pharmaceuticals's capex changed year-over-year?
- Jazz Pharmaceuticals's capex increased by 41.7% year-over-year, from $13.9M to $19.7M.
- What is the long-term trend for Jazz Pharmaceuticals's capex?
- Over 3 years (2021 to 2025), Jazz Pharmaceuticals's capex has grown at a 28.6% compound annual growth rate (CAGR), from $27.64M to $58.75M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Jazz Pharmaceuticals's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude